• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非维生素 K 口服抗凝剂与维生素 K 拮抗剂治疗的心房颤动患者心房血栓形成的频率:系统评价和荟萃分析。

Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis.

机构信息

Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.

Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.

出版信息

Eur J Med Res. 2018 Oct 23;23(1):49. doi: 10.1186/s40001-018-0350-9.

DOI:10.1186/s40001-018-0350-9
PMID:30352632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6198509/
Abstract

BACKGROUND

To assess the frequency of left atrium/left atrial appendage (LA/LAA) thrombus under treatment with non-vitamin K oral anticoagulants (NOACs) in comparison with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (AF).

METHODS

PubMed, Web of Science™, EMBASE and the Cochrane Library databases were searched for studies comparing NOACs with VKAs in AF patients who underwent diagnostic transoesophageal echocardiography (TEE).

RESULTS

A total of four trials were considered eligible and were included in the meta-analysis. Four RCTs comprising n = 2397 AF patients (NOACs: n = 1412, VKAs: n = 985) were included in the meta-analysis. The frequency of LA/LAA thrombus formation under treatment with NOACs was similar to VKAs [odds ratio (OR) 1.14, 95% confidence intervals (95% CIs) 0.97-1.65, p = 0.48]. Both treatment groups revealed an approximately 5% frequency of thrombus formation, although a precise calculation is not possible due to Simpson paradox. Indications of heterogeneity between the included trials were not found (χ test p = 0.99, I = 0%).

CONCLUSIONS

The findings of this meta-analysis suggest that NOACs are similar to VKAs regarding the frequency of LA/LAA thrombus in patients with AF. An unknown number of patients in the original studies did not receive sufficient anticoagulation for at least 3 weeks prior to TEE examination, and therefore the present results should be interpreted with caution. Systematic review registration- http://www.crd.york.ac.uk/PROSPERO . Unique identifier: PROSPERO CRD42017059293.

摘要

背景

评估非维生素 K 口服抗凝剂(NOACs)与维生素 K 拮抗剂(VKAs)在非瓣膜性心房颤动(AF)患者中的左心房/左心耳(LA/LAA)血栓形成频率。

方法

检索 PubMed、Web of Science™、EMBASE 和 Cochrane 图书馆数据库,比较 AF 患者经诊断性经食管超声心动图(TEE)检查的 NOACs 与 VKAs 的研究。

结果

共有 4 项试验被认为符合条件,并纳入荟萃分析。荟萃分析纳入了 4 项 RCT,共 2397 例 AF 患者(NOACs:n=1412,VKAs:n=985)。NOACs 治疗下 LA/LAA 血栓形成的频率与 VKAs 相似[比值比(OR)1.14,95%置信区间(95%CI)0.97-1.65,p=0.48]。两组的血栓形成频率均约为 5%,但由于辛普森悖论,无法精确计算。未发现纳入试验之间存在异质性迹象(χ检验 p=0.99,I=0%)。

结论

本荟萃分析的结果表明,NOACs 在 AF 患者中与 VKAs 相比,LA/LAA 血栓形成的频率相似。由于对 TEE 检查前至少 3 周进行充分抗凝治疗的患者数量未知,因此应谨慎解释本研究结果。系统评价注册- http://www.crd.york.ac.uk/PROSPERO. 独特标识符:PROSPERO CRD42017059293。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/c05af83a0c71/40001_2018_350_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/1867840c9a11/40001_2018_350_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/450fd61c1322/40001_2018_350_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/c05af83a0c71/40001_2018_350_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/1867840c9a11/40001_2018_350_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/450fd61c1322/40001_2018_350_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcbc/6198509/c05af83a0c71/40001_2018_350_Fig4_HTML.jpg

相似文献

1
Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis.非维生素 K 口服抗凝剂与维生素 K 拮抗剂治疗的心房颤动患者心房血栓形成的频率:系统评价和荟萃分析。
Eur J Med Res. 2018 Oct 23;23(1):49. doi: 10.1186/s40001-018-0350-9.
2
The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.亚洲心房颤动患者中新型口服抗凝药与维生素 K 拮抗剂之间胃肠道出血风险的荟萃分析。
Int J Environ Res Public Health. 2020 Dec 27;18(1):137. doi: 10.3390/ijerph18010137.
3
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.非维生素K拮抗剂口服抗凝剂用于心房颤动和静脉血栓栓塞的有效性和安全性:一项系统评价和荟萃分析
Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28.
4
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists.达比加群、利伐沙班和维生素K拮抗剂治疗下左心房异常的发生率。
Eur J Med Res. 2016 Oct 21;21(1):41. doi: 10.1186/s40001-016-0235-8.
5
Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis.不同抗凝策略对心房颤动患者行经食管超声心动图检查结果的影响比较:系统评价和荟萃分析。
BMC Cardiovasc Disord. 2019 Nov 26;19(1):261. doi: 10.1186/s12872-019-1209-x.
6
The Efficacy of Non-Vitamin K Antagonist Oral Anticoagulants in the Prevention of Left Atrial Thrombus in Patients With Atrial Fibrillation Compared With Vitamin K Antagonists: A Meta-Analysis.非维生素 K 拮抗剂口服抗凝剂与维生素 K 拮抗剂在预防房颤患者左心房血栓形成中的疗效比较:一项荟萃分析。
Heart Surg Forum. 2020 Oct 12;23(6):E733-E739. doi: 10.1532/hsf.3203.
7
Left atrial appendage thrombus in patients with atrial fibrillation who underwent oral anticoagulation.接受口服抗凝治疗的心房颤动患者的左心耳血栓。
Cardiol J. 2024;31(3):461-471. doi: 10.5603/CJ.a2022.0054. Epub 2022 Jun 15.
8
Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.非维生素 K 拮抗剂口服抗凝剂在心房颤动导管消融中的安全性和有效性:系统评价和荟萃分析。
Cardiovasc Ther. 2018 Oct;36(5):e12457. doi: 10.1111/1755-5922.12457. Epub 2018 Jul 30.
9
Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients.新型抗凝剂与维生素 K 拮抗剂在非瓣膜性心房颤动转复中的比较 - 超过 17000 例患者的荟萃分析。
Sci Rep. 2019 Feb 28;9(1):3011. doi: 10.1038/s41598-019-39925-5.
10
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.维生素K与非维生素K拮抗剂口服抗凝药用于非瓣膜性心房颤动的真实世界研究
Eur J Intern Med. 2016 Sep;33:42-6. doi: 10.1016/j.ejim.2016.06.022. Epub 2016 Jul 6.

引用本文的文献

1
Effect of anticoagulation on the age distribution of thrombi in stroke patients with non-valvular atrial fibrillation.抗凝治疗对非瓣膜性心房颤动卒中患者血栓年龄分布的影响。
BMJ Neurol Open. 2025 Jul 3;7(2):e000954. doi: 10.1136/bmjno-2024-000954. eCollection 2025.
2
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation.缺血性卒中后尽管进行了抗凝治疗,左心耳封堵与标准治疗的比较
JAMA Neurol. 2024 Sep 23;81(11):1150-8. doi: 10.1001/jamaneurol.2024.2882.
3
Characteristics of non-valvular atrial fibrillation with left atrial appendage thrombus who are undergoing appropriate oral anticoagulation therapy.

本文引用的文献

1
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.依度沙班与华法林/维生素 K 拮抗剂在拟行电复律的心房颤动患者中的比较:EMANATE 试验。
Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.
2
Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).基线卒中风险和出血风险对心房颤动患者华法林国际标准化比值控制的影响(来自TREAT-AF研究)
Am J Cardiol. 2017 Jan 15;119(2):268-274. doi: 10.1016/j.amjcard.2016.09.045. Epub 2016 Oct 8.
3
正在接受适当口服抗凝治疗的非瓣膜性心房颤动合并左心耳血栓患者的特征
Int J Cardiovasc Imaging. 2022 May;38(5):941-951. doi: 10.1007/s10554-021-02403-z. Epub 2022 Mar 30.
4
Limitations in Contemporary Pharmacological Stroke Prevention Therapies in Atrial Fibrillation: A Descriptive Literature Review.当代房颤药理学卒中预防疗法的局限性:描述性文献综述
J Clin Med. 2023 Oct 18;12(20):6594. doi: 10.3390/jcm12206594.
5
Percutaneous left atrial appendage closure using the LAmbre device in patients with atrial fibrillation and left atrial appendage thrombus.使用LAmbre装置对心房颤动合并左心耳血栓患者进行经皮左心耳封堵术。
Front Cardiovasc Med. 2022 Nov 24;9:1071119. doi: 10.3389/fcvm.2022.1071119. eCollection 2022.
6
Electric cardioversion in patients treated with oral anticoagulants: embolic material in the left atrial appendage.接受口服抗凝剂治疗的患者进行心脏电复律:左心耳内的栓子物质
Cardiovasc J Afr. 2023;34(3):181-188. doi: 10.5830/CVJA-2022-060. Epub 2022 Dec 5.
7
Left atrial appendage thrombus in patients with atrial fibrillation who underwent oral anticoagulation.接受口服抗凝治疗的心房颤动患者的左心耳血栓。
Cardiol J. 2024;31(3):461-471. doi: 10.5603/CJ.a2022.0054. Epub 2022 Jun 15.
8
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?三周口服抗凝治疗是否足以安全进行心房颤动转复?
Medicina (Kaunas). 2021 May 31;57(6):554. doi: 10.3390/medicina57060554.
9
Stroke prevention strategies in high-risk patients with atrial fibrillation.高危房颤患者的卒中预防策略。
Nat Rev Cardiol. 2021 Apr;18(4):276-290. doi: 10.1038/s41569-020-00459-3. Epub 2020 Oct 27.
10
Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban.房颤患者在接受电复律或导管消融术时,尽管持续使用非维生素K拮抗剂口服抗凝药治疗,仍发生左心耳血栓形成:达比加群与利伐沙班的比较
Cardiol Res Pract. 2020 Sep 17;2020:1206402. doi: 10.1155/2020/1206402. eCollection 2020.
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists.
达比加群、利伐沙班和维生素K拮抗剂治疗下左心房异常的发生率。
Eur J Med Res. 2016 Oct 21;21(1):41. doi: 10.1186/s40001-016-0235-8.
4
Effect of Metabolic Syndrome on Risk Stratification for Left Atrial or Left Atrial Appendage Thrombus Formation in Patients with Nonvalvular Atrial Fibrillation.代谢综合征对非瓣膜性心房颤动患者左心房或左心耳血栓形成风险分层的影响。
Chin Med J (Engl). 2016 Oct 20;129(20):2395-2402. doi: 10.4103/0366-6999.191744.
5
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.依度沙班与依诺肝素 - 华法林用于房颤复律患者的疗效比较(ENSURE - AF):一项随机、开放标签的3b期试验。
Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30.
6
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
7
Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).心房颤动或心房扑动患者左心房血栓溶解情况:利伐沙班前瞻性研究(X-TRA)及提供基线数据的回顾性观察登记研究(CLOT-AF)结果
Am Heart J. 2016 Aug;178:126-34. doi: 10.1016/j.ahj.2016.05.007. Epub 2016 May 17.
8
Detection of LA and LAA Thrombus by CMR in Patients Referred for Pulmonary Vein Isolation.经胸超声心动图与经食管超声心动图在左心耳封堵术中的应用比较
JACC Cardiovasc Imaging. 2016 Jul;9(7):809-818. doi: 10.1016/j.jcmg.2015.11.029. Epub 2016 May 25.
9
Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation.比较 ATRIA、CHADS2 和 CHA2DS2-VASc 卒中风险评分在预测大型瑞典房颤患者缺血性卒中中的作用。
Eur Heart J. 2016 Nov 7;37(42):3203-3210. doi: 10.1093/eurheartj/ehw077. Epub 2016 Mar 3.
10
The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.心房颤动类型对血栓栓塞、死亡率和出血风险的影响:系统评价和荟萃分析。
Eur Heart J. 2016 May 21;37(20):1591-602. doi: 10.1093/eurheartj/ehw007. Epub 2016 Feb 16.